EGFR and hepatocellular carcinoma: Studies have shown that the activation of EGFR significantly inhibits the response of HCC to the tyrosine kinase inhibitor lenvatinib, and this resistance is overcome after inhibition of the EGFR -STAT3-ABCB1 pathway [47, 48].